Do gabapentin or pregabalin directly modulate the µ receptor?
Background Pregabalin and gabapentin improve neuropathic pain symptoms but there are emerging concerns regarding their misuse. This is more pronounced among patients with substance use disorder, particularly involving opioids. Co-ingestion of gabapentinoids with opioids is increasingly identified in...
Päätekijät: | Preeti Manandhar, Bridin Patricia Murnion, Natasha L. Grimsey, Mark Connor, Marina Santiago |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
PeerJ Inc.
2021-04-01
|
Sarja: | PeerJ |
Aiheet: | |
Linkit: | https://peerj.com/articles/11175.pdf |
Samankaltaisia teoksia
-
Gabapentin and pregabalin exposures reported to United States poison centers, 2012–2022
Tekijä: Emily J.R. Carter, et al.
Julkaistu: (2024-11-01) -
A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder
Tekijä: Qin Xiang Ng, et al.
Julkaistu: (2021-08-01) -
Efficacy and safety of pregabalin and gabapentin in spinal stenosis: a systematic review and meta-analysis
Tekijä: Telmo Martínez, et al.
Julkaistu: (2023-11-01) -
Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
Tekijä: Payal H. Desai, PharmD, BCCCP, et al.
Julkaistu: (2021-07-01) -
Gabapentin and Pregabalin in chronic neuropathic pain: cost efficacy evaluation
Tekijä: Paolo Marchettini, et al.
Julkaistu: (2005-05-01)